Investment area

Growth Investments

Planetary Health Investments


North America

Date of investment

July 2019

LanzaTech is turning the global carbon challenge into an opportunity with the potential to displace 30% of crude oil use today and reduce global CO2 emissions by 10%.

Visit site


Robert Ghenchev

Managing Partner

Departments: Growth Investments, Novo Holdings Equity US Inc., Life Sciences Operating Committee

Robert joined Novo Holdings in January 2018 and serves as a Managing partner and head of  Growth Investments.

Before joining Novo Holdings, Robert was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London.

Robert holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.


Helen Gaffney


Department: Principal Investments

Helen joined Novo Holdings A/S in October 2018 in Principal Investments. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments.

Prior to joining Novo Holdings A/S, Helen worked as an investment professional with the private equity firm OpCapita in London. During this time, she worked actively with existing portfolio companies as well as assessing new acquisition opportunities across Europe. Before this, Helen worked as a mergers and acquisitions generalist at Moelis & Company in London.

Helen holds an MBA from Copenhagen Business School and a BA degree in Natural Sciences from the University of Cambridge.


Anders Bendsen Spohr

Senior Partner, Head of Planetary Health Investments

Departments: Life Sciences Operating Committee, Planetary Health Investments

Anders joined Novo Holdings A/S in 2017.
Anders is Sr Partner and Head of the Planetary Health Investments team.

Prior to joining Novo Holdings, Anders was employed as VP in Xellia Pharmaceuticals heading up the Global Product Supply. Other previous employments include EVP, Global Product Supply at Leo Pharma A/S and VP Global Supply Chain at Novozymes A/S.

Anders holds a PhD in Biotechnology and a MSc in Chemical Engineering from Technical University of Denmark as well as a graduate diploma in Business Administration (International Business) from Copenhagen Business School.